MAPT and Alzheimer disease: In particular, we conducted a targeted assessment of markers of AD pathology (amyloid-β40 [Aβ40] and Aβ42) and neuronal injury (neurofilament-light [NfL], total-tau [t-tau]), and applied the Olink proteomic platform to identify the secreted factors in circulation that are associated with cognitive resilience in APOEε4 carriers.